These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36642317)

  • 1. Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design.
    Shao HP; Wang TH; Zhai HL; Bi KX; Zhao BQ
    Chem Biol Interact; 2023 Feb; 371():110352. PubMed ID: 36642317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
    Amin SA; Banerjee S; Gayen S; Jha T
    Eur J Med Chem; 2021 Apr; 215():113294. PubMed ID: 33618158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attention Mechanism-Based Graph Neural Network Model for Effective Activity Prediction of SARS-CoV-2 Main Protease Inhibitors: Application to Drug Repurposing as Potential COVID-19 Therapy.
    Wu Y; Li K; Li M; Pu X; Guo Y
    J Chem Inf Model; 2023 Nov; 63(22):7011-7031. PubMed ID: 37960886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
    Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
    Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking-Based Evidence for the Potential of ImmunoDefender: A Novel Formulated Essential Oil Blend Incorporating Synergistic Antiviral Bioactive Compounds as Promising Mpro Inhibitors against SARS-CoV-2.
    Ksouri A; Klouz A; Bouhaouala-Zahar B; Moussa F; Bezzarga M
    Molecules; 2023 May; 28(11):. PubMed ID: 37298772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An
    Mishra B; Ballaney P; Saha G; Shinde A; Banerjee S; Thimmakondu VS; Aduri R
    J Biomol Struct Dyn; 2023 May; 41(8):3167-3186. PubMed ID: 35261325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
    Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS
    Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depicting the inhibitory potential of polyphenols from
    Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
    J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").
    Cayona R; Creencia E
    Med Chem; 2022; 18(3):364-381. PubMed ID: 34148541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico study of alkaloids with quercetin nucleus for inhibition of SARS-CoV-2 protease and receptor cell protease.
    Mohebbi A; Eskandarzadeh M; Zangi H; Fatehi M
    PLoS One; 2024; 19(4):e0298201. PubMed ID: 38626042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro.
    Silva RC; Freitas HF; Campos JM; Kimani NM; Silva CHTP; Borges RS; Pita SSR; Santos CBR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2.
    Anton DB; Galvez Bulhões Pedreira J; Zvirtes ML; Laufer SA; Ducati RG; Goettert M; Saraiva Macedo Timmers LF
    J Chem Inf Model; 2023 Jul; 63(13):4138-4146. PubMed ID: 37329322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
    Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
    Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.